<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941207-0-00052</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <TABLE>  <!-- PJG tableformat 2,L2,i1,xs40,r75 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=4 --> Table 1  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1CFR section  <!-- PJG 007 0150 intable --> 1Device <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=01 g=1 f=4 --> 862.2270 <!-- PJG 007 0104 intable --> Thin-layer chromatography system for clinical use. 862.2310 <!-- PJG 007 0104 intable --> Clinical sample concentrator.  <!-- PJG 0012 frnewline --> 862.2320 <!-- PJG 007 0104 intable --> Beta or gamma counter for clinical use. <!-- PJG 0012 frnewline --> 862.2485 <!-- PJG 007 0104 intable --> Electrophoresis apparatus for clinical use. <!-- PJG 0012 frnewline --> 862.2720 <!-- PJG 007 0104 intable --> Plasma oncometer for clinical use. <!-- PJG 0012 frnewline --> 862.2800 <!-- PJG 007 0104 intable --> Refractometer for clinical use. <!-- PJG 0012 frnewline --> 862.2920 <!-- PJG 007 0104 intable --> Plasma viscometer for clinical use. <!-- PJG 0012 frnewline --> 864.2280 <!-- PJG 007 0104 intable --> Cultured animal and human cells. <!-- PJG 0012 frnewline --> 866.5570 <!-- PJG 007 0104 intable --> Lactoferrin immunological test system. <!-- PJG 0012 frnewline --> 868.5620 <!-- PJG 007 0104 intable --> Breathing mouthpiece. <!-- PJG 0012 frnewline --> 868.5675 <!-- PJG 007 0104 intable --> Rebreathing device. <!-- PJG 0012 frnewline --> 868.5700 <!-- PJG 007 0104 intable --> Nonpowered oxygen tent. <!-- PJG 0012 frnewline --> 872.3740 <!-- PJG 007 0104 intable --> Retentive and splinting pin. <!-- PJG 0012 frnewline --> 872.3810 <!-- PJG 007 0104 intable --> Root canal post. <!-- PJG 0012 frnewline --> 872.6100 <!-- PJG 007 0104 intable --> Anesthetic warmer. <!-- PJG 0012 frnewline --> 886.5850 <!-- PJG 007 0104 intable --> Sunglasses (nonprescription). <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=4 --> FDA will address these devices in a future issue of the Federal Register. <!-- PJG 0012 frnewline --> FDA received no adverse comments on 148 of the devices that it proposed be exempted from the requirement of premarket notification. For these 148 devices, FDA has concluded that manufacturers' submissions of premarket notifications are unnecessary for the protection of the public health and that the agency's review of such submissions will not advance its public health mission. Thus, FDA is finalizing the exemptions for these 148 devices from premarket notification procedures.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=4 --> IV. Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> The agency has determined under 21 CFR 25.24(e)(2) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=4 --> V. Analysis of Impacts <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> FDA has examined the impacts of the final rule under Executive Order 12866 and the Regulatory Flexibility Act (Pub. L. 96&hyph;354). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The agency believes that this final rule is consistent with the regulatory philosophy and principles identified in the Executive Order. In addition, the final rule is not a significant regulatory action as defined by the Executive Order and so is not subject to review under the Executive Order. <!-- PJG 0012 frnewline --> The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Because this final rule reduces a regulatory burden by exempting manufacturers of devices subject to the final rule from the requirements of premarket notification, the agency certifies that the final rule will not have a significant economic impact on a substantial number of small entities. Therefore, under the Regulatory Flexibility Act, no further analysis is required.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=4 --> List of Subjects <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 864 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Blood, Medical devices, Packaging and containers. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Parts 868, 870, 872, 874, 876, 878, 880, 882, 888, and 890 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Medical devices. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 866 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Biologics, Laboratories, Medical devices. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 886 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Medical devices, Ophthalmic goods and services. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=4 --> 21 CFR Part 892 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Medical devices, Radiation protection, X-rays. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=4 --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 864, 866, 868, 870, 872, 874, 876, 878, 880, 882, 886, 888, 890, and 892 are amended as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=4 --> PART 864_HEMATOLOGY AND PATHOLOGY DEVICES <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> 1. The authority citation for 21 CFR part 864 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 501, 510, 513, 515, 520, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351, 360, 360c, 360e, 360j, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 864.5350 is amended by revising paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;864.5350  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Microsedimentation centrifuge. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Classification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Class I. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter. <!-- PJG 0012 frnewline --> 3. Section 864.7660 is amended by revising paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;864.7660  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Leukocyte alkaline phosphatase test. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Classification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Class I. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. Section 864.7675 is amended by revising paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;864.7675  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Leukocyte peroxidase test. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Classification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Class I. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 5. Section 864.7900 is amended by revising paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;864.7900  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Thromboplastin generation test. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Classification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Class I. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 6. Section 864.8500 is amended by revising paragraph (b) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;864.8500  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Lymphocyte separation medium. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Classification.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Class I. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 866_IMMUNOLOGY AND MICROBIOLOGY DEVICES <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 7. The authority citation for 21 CFR part 866 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Secs. 501, 510, 513, 515, 520, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351, 360, 360c, 360e, 360j, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 8. Section 866.5170 is amended by revising paragraph (b) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            